Studies have shown that EGFR is overexpressed and abnormally expressed in many solid tumors and is associated with cell proliferation, angiogenesis, tumor invasion and tumor metastasis.48 Among them, non-small cell lung cancer(NSCLC), one of the most aggressive cancers, is closely related to aberrant EGFR signaling.49 Although three generations of small-molecule EGFR inhibitors have been approved by FDA for the treatment of NSCLC patients, drug resistance resulting from continuously heterogeneous mutations (EGFRC797S) remains a problem that inhibitors cannot overcome.50 This evidence concerns the gene EGFR and neoplasm.